My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
I am undergraduate student majoring in biotechnology and minoring in finance as well business administration.
As a biotechnology major, I have excellent capacity to understand biotechnology related companies, especially the nature of their products. My financial background includes my role as co-portfolio director for the Financial Management Association - a student association.
For the most part, I am a self thought investor who thoroughly enjoy the adventure that is investing. I have thought myself from knowing nothing about finance to investing in the stock market and also trading commodity futures.
After two years of learning from the Seeking Alpha community, I think now is the time for me to do my part and contribute to this awesome community.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
PRIMARY OBJECTIVE: ... Income Replacement!
Escape velocity is the speed that an object needs to be traveling to break free of the planet's gravitational pull and leave it without further propulsion.
This portfolio is looking for the point where the income being generated can allow the holder of this portfolio to escape the gravitational pull of the market and economic forces of worrying about share prices.
The objective is to generate enough income from assets that the only selling of shares will become an option, not a necessity to survive. Therefore, with enough income being generated, it minimizes the fear of meaningful market corrections as dividends are based on the number of shares owned, not the share price.
Bob is retired from a career in law enforcement including more than 20 years as an instructor of Investigative Interviewing. He is a Dividend Growth investor using dividend yield from low beta stocks for income and preservation of capital. Bob has self managed his portfolio since early in 2011. He hopes to encourage discussion among those already in retirement and receiving income from their portfolios.
My curent portfolio is available here:
I believe that everyone needs a portfolio business plan.
Here's a copy of ours:: http://seekingalpha.com/article/2426965-our-retirement-portfolio-business-plan-legacy-edition-part-two
A list of Dividend Growth Safety Superstars for the past decade is available here: http://seekingalpha.com/article/2255863-a-review-of-the-dividend-safety-superstars
StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
Dr. Ahanotu is a graduate of Stanford University with over twenty years of experience doing analytic modeling, executing pricing strategies through price optimization, and implementing, developing, and selling enterprise software. He adds to this industry experience another five overlapping years of research in knowledge management and organizational learning. Duru Ahanotu, Ph.D. founded Ahan Analytics, LLC to deliver sustainable, data-driven approaches for improving business performance. He recognizes the unique challenges companies face in leveraging their data to increase revenues, become more efficient, and drive profitability.
Before launching Ahan Analytics, LLC, Dr. Ahanotu was last a Sales Consultant in the Advertiser and Publisher Solutions (APS) group within Microsoft Advertising. In this capacity, he provided product knowledge, functional expertise, and technical support to APS account executives who sold APS’s suite of media monetization products. He led product demonstrations and increased the productivity of the sales team by training and certifying employees on the use and demonstration of the software. Dr. Ahanotu took on this role after Microsoft acquired his former employer Rapt, Inc. Rapt provided software solutions for maximizing revenue and yield for online media publishers.
With Rapt, Dr. Ahanotu last served as an Engagement Manager for a software implementation for a $100 million on-line publisher with a rapidly growing business. With his project team, Dr. Ahanotu created and coordinated novel approaches to inventory forecasting, structuring of product hierarchies, and ETL across software systems for order management, advertising delivery, and Rapt’s software. He also generated a step-by-step methodology for interpreting and using the results of price optimization.
As a Solutions Architect, Dr. Ahanotu served as the lead Solutions Consultant on client engagements and provided technical assistance and guidance to Solutions Consultants on other projects. Dr. Ahanotu designed and implemented price optimization solutions, demonstrating expertise in mathematical modeling, pricing, data analysis, SQL, and relational data models. He led discussions with customers and internal teams to improve implementation processes and product design.
Dr. Ahanotu held oversight responsibility for the analytic modeling for two projects using Price Director, Rapt’s price optimization software. Each project supported pricing decisions in Fortune 50 businesses: one business was a leading online media publisher, and the other was a rapidly growing technology company in a low margin business. Dr. Ahanotu helped the latter client integrate Price Director into pricing workflow. As part of this first-ever client implementation of Price Director, he worked closely with Product Management, Analytic Development, and Software Engineering to ensure that early-stage product functionality met client needs.
Dr. Ahanotu contributed several new methodologies for implementing Price Director analytics and conceptual frameworks for training clients on these analytics. He is a contributor on a related Rapt patent: “Method and System for Producing Optimized Prices for Products for Sale.” Dr. Ahanotu presented a white paper on the pricing of New Product Introductions at the 2006 INFORMS Annual Meeting. The Professional Pricing Society published this paper in The Journal of Professional Pricing (Vol. 16, No. 1, First Quarter 2007) as “Pricing New Products: Turning Portfolio Uncertainty Into Profits.”
Prior to Rapt, Dr. Ahanotu was a consultant with Integral, Inc, a small strategic management consulting firm. During his three-year tenure, he consulted on product development and technology strategy focused on high tech and pharmaceutical companies. Prior to Integral, he developed mathematical programming algorithms for managing and optimizing “Y2K” projects as an independent contractor. Prior to this work, he implemented expert systems for diagnosing and troubleshooting automotive and semiconductor manufacturing equipment as a Business Solutions Project Manager and Consultant for Expert Edge, Inc.
Dr. Ahanotu earned a Master’s and Ph.D. in Engineering-Economic Systems (1999), a B.S. in Mechanical Engineering, and Honors in Values, Technology, Science, and Society (1991) - all at Stanford University.
The biotechnology sector has fascinated me for a long time, and my experience working in "big pharma" only increased my interest.
My goals with my research are simple - first and foremost, I strive to identify undervalued stocks that have future catalysts that can greatly push the price per share up. Another area that I focus on is combatting the "naysayers" - those individuals who either due to a lack of due diligence or who have ulterior motives - who spread news, gossip, and other misinformation. Most retail investors do not have an opportunity to conduct hours of research a day to sort through the vast array of information, and thus can be easily influenced by positive or negative information that may not be entirely accurate.
In terms of my Seeking Alpha article writing, it is my hope to identify potential opportunities that may be overlooked, pitfalls that may be avoided, and to also generate discussion about potential deals or binary events that could impact investors in the biotech sector.
Please note that the article that you are reading here was originally written on my blog and is republished in Seeking Alpha and other forums. Consequently, I neither track nor respond to comments here. I am sorry! ================ Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
I do not believe in good or bad stocks, only in good or bad prices for them. I am not afraid of volatility, and if I believe in a stock's prospects I will chase it all the way down to pennies. I am a patient investor, and if I like a company I will generally commit for the long haul. I rarely go short - the potential benefits in my view rarely compensate for the risks incurred. I sometimes use leverage, but in a disciplined way. Leverage and emotions don't mix. I always look at the math, numbers, and accounting behind any investment target or strategy. I believe that in finance the devil is in the details, and that most of the "macro outlook" commentary that pervades the financial media and financial forums is uninformed, pretentious mumbo-jumbo. I invest in many industrial sectors: energy (mainly oil & gas), mining, transportation, banking, and real estate. I do however shy away from segments of the market that I do not understand (e.g., biotechnology).
I do not render individualized investment advice, and I do not manage or solicit for management any third-party capital. My analyses are solely for informational/educational purposes, and may contain errors.
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
After two decades as an investment banker, analyst or portfolio manager for major Wall Street firms, in 1995 started his own investment firm specializing in M&A and portfolio management for high wealth individuals.
Charles (Chuck) C. Carnevale is the creator of F.A.S.T. Graphs™. Chuck is also co-founder of an investment management firm. He has been working in the securities industry since 1970: he has been a partner with a private NYSE member firm, the President of a NASD firm, Vice President and Regional Marketing Director for a major AMEX listed company, and an Associate Vice President and Investment Consulting Services Coordinator for a major NYSE member firm. Prior to forming his own investment firm, he was a partner in a 30-year-old established registered investment advisory in Tampa, Florida. Chuck holds a Bachelor of Science in Economics and Finance from the University of Tampa. Chuck is a sought-after public speaker who is very passionate about spreading the critical message of prudence in money management. Chuck is a Veteran of the Vietnam War and was awarded both the Bronze Star and the Vietnam Honor Medal.